In order to represent therelatively low expression profile of NKX3.1 and to investigate itscontribution to the EMT process in prostate cancer, we depleted theNKX3.1 expression by CRISPR (Figure 3A). This evidence concerns the gene NKX3-1 and prostate carcinoma.